32
total announcements
BAJAJHCARE.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹1,115 Cr
P/E (TTM)
47.8
EPS (TTM)
₹6.93
52W Low
₹272.35
52W High
₹490.00
Dividend Yield
0.46%
Beta
0.28
Price / Book
2.0
Debt / Equity
46.7
Revenue (TTM)
₹628 Cr
Gross Margin
48.73%
Operating Margin
13.12%
Bajaj Healthcare Limited
Bajaj Healthcare Limited has received approval from the Hon'ble National Company Law Tribunal (NCLT) for the acquisition of Genrx Pharmaceuticals Private Limited on a going concern basis.
Bajaj Healthcare Limited
Bajaj Healthcare Limited has scheduled an earnings call to discuss its financial performance for the quarter and half year ended September 30, 2026. The call will be held on October 19, 2026, at 5:00 pm IST, and can be accessed through conference dial-in numbers or online pre-registration.
Bajaj Healthcare Limited
Bajaj Healthcare Limited has informed the Exchange about the sale of an undertaking to Spa Vet Private Limited and Indosol Pure Technologies Private Limited for Rs. 14.67 Crores. The transaction does not fall within related party transactions and the trading window for dealing in securities of the company remains closed.
Bajaj Healthcare Limited
Bajaj Healthcare Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, received from its Registrar and Share Transfer Agent, MUFG Intime India Private Limited, for the quarter ended September 30, 2026.
Bajaj Healthcare Limited
Bajaj Healthcare Limited has closed its trading window for insiders due to the upcoming declaration of its un-audited financial results for the quarter and half year ended September 30, 2026.
Bajaj Healthcare Limited
Bajaj Healthcare Limited has submitted the Exchange a copy Scrutinizers report of Annual General Meeting held on September 21, 2026, and informed the Exchange regarding voting results.
Bajaj Healthcare Limited
Bajaj Healthcare Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 21, 2026. The meeting was held through Video Conferencing and had a quorum of 49 members. The Chairman and Managing Director, Mr. Sajankumar R. Bajaj, declared the meeting in order and the Managing Director, Mr. Anil Champalal Jain, briefed the members on the financial performance of the Company during the financial year 2025-26.
Bajaj Healthcare Limited
Bajaj Healthcare Limited has announced a record date of September 14, 2026, for the purpose of determining entitlement of shareholders for payment of a 30% final dividend, i.e., ₹1.50 per equity share, for the financial year 2025-26.
Bajaj Healthcare Limited
Bajaj Healthcare Limited has informed the Exchange about the dispatch of Notice of 33rd Annual General Meeting & Annual Report for the financial year 2025-26 and E-Voting Information published in two newspapers.
Bajaj Healthcare Limited
Bajaj Healthcare Limited has informed the Exchange regarding the Inland Letters sent to Shareholders, providing the web-link to access the Annual Report 2025-26 to those Shareholders who have not registered their e-mail addresses with the Company or their Depository Participants (DPs).
Bajaj Healthcare Limited
Bajaj Healthcare Limited has informed the Exchange regarding Business Responsibility and Sustainability Report for the financial year 2025-26.
Bajaj Healthcare Limited
Bajaj Healthcare Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 21, 2026.
Bajaj Healthcare Limited
Bajaj Healthcare Limited has informed the Exchange about Copy of Newspaper Publication with respect to 33rd Annual General Meeting of the Company. The Company will hold its 33rd Annual General Meeting on September 21, 2026, through Video Conferencing or Other Audio Visual Means.
Bajaj Healthcare Limited
Bajaj Healthcare Limited has informed the Exchange regarding the allotment of 2,500 equity shares to eligible employees under the Bajaj Healthcare Limited Employee Stock Option Scheme 2024, upon the exercise of 2,500 vested stock options at an exercise price of ₹5/- per stock option.
Bajaj Healthcare Limited
Bajaj Healthcare Limited has informed the Exchange about the allotment of 2,500 equity shares pursuant to the exercise of employee stock options under the Bajaj Healthcare Limited Employee Stock Option Scheme 2024.
Bajaj Healthcare Limited
Bajaj Healthcare Limited has received approval from the Drug Controller General of India (DCGI) to manufacture and market Cenobamate API and Tablets in six strengths, marking a significant milestone in the Company's journey towards bringing advanced therapies to patients.
Bajaj Healthcare Limited
Bajaj Healthcare Limited's bank loan facilities have been upgraded to 'IND A' from 'IND A-' with a Stable Outlook, and short-term bank loan facilities have been upgraded to 'IND A1' from 'IND A2+', by India Ratings and Research (Ind-Ra).
Bajaj Healthcare Limited
Bajaj Healthcare Limited has announced the transcript of its Q1FY27 earnings call, highlighting its strategic focus on API and formulation businesses, including the expansion of its peptide manufacturing facility and the launch of new products such as Cenobamate Tablets and Posaconazole 300 mg tablet.
Bajaj Healthcare Limited
Bajaj Healthcare Limited has informed the Exchange about the publication of Un-Audited Financial Results for the quarter ended June 30, 2026, in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Bajaj Healthcare Limited
Bajaj Healthcare Limited has informed the Exchange about the link of the recording of the earnings call for Q1FY27, which is available on the company's website.